Name | Balsalazide |
Synonyms | 80573-04-2 balsalazido Balsalazide BALSALAZIDE BALSALAZIDE SODIUM BALSALZIDE DISODIUM BALSALAZIDE DISODIUM SALT 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-benzoicaci(e (E)-5-[[4-[[(2-Carboxyethyl)amino]-carbonyl]phenyl]azo-2-hydroxybenzoic acid Benzoic acid, 5-((1E)-(4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy- (3Z)-3-({4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazono)-6-oxocyclohexa-1,4-diene-1-carboxylic acid (3E)-3-({4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazono)-6-oxocyclohexa-1,4-diene-1-carboxylic acid |
CAS | 80573-04-2 |
EINECS | 617-116-8 |
InChI | InChI=1/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,19H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-12- |
Molecular Formula | C17H15N3O6 |
Molar Mass | 357.32 |
Density | 1.44±0.1 g/cm3(Predicted) |
Melting Point | 254-255?C |
Boling Point | 729.6±60.0 °C(Predicted) |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 0Pa at 20℃ |
Appearance | Solid |
Color | Yellow to Beige |
pKa | 2.97±0.10(Predicted) |
Storage Condition | -20°C Freezer |
Refractive Index | 1.649 |
Use | Anti-ulcerative colitis drugs. |
In vivo study | At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.799 ml | 13.993 ml | 27.986 ml |
5 mM | 0.56 ml | 2.799 ml | 5.597 ml |
10 mM | 0.28 ml | 1.399 ml | 2.799 ml |
5 mM | 0.056 ml | 0.28 ml | 0.56 ml |